Abionyx PharmaLTS:0RAG +1.45%29 Days Payable is 155.15 as of Dec. 2025, which is 5% below its 10-year median of 162.90. GuruFocus rates LTS:0RAG with a GF Score™ of 29/100 and a GF Value™ of €0.85 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, Abionyx Pharma ranks better than 57.53% on this metric.
The historical rank and industry rank for Abionyx Pharma's Days Payable or its related term are showing as below:
LTS:0RAG'
s Days Payable Range Over the Past 10 Years
Min: 149.38 Med: 162.9 Max: 2244.4
Current: 152.18
During the past 13 years, Abionyx Pharma's highest Days Payable was 2244.40. The lowest was 149.38. And the median was 162.90.
LTS:0RAG's Days Payable is ranked better than 57.53% of 704
companies
in the Biotechnology industry
Industry Median: 113.56
vs LTS:0RAG: 152.18
Abionyx Pharma's Days Payable
increased
from Dec. 2024 (152.27) to Dec. 2025 (155.15).
It may suggest that Abionyx Pharmadelayed paying its suppliers.
Abionyx Pharma Days Payable Related Terms
Abionyx Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Abionyx Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAG vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Abionyx Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abionyx Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Abionyx Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Abionyx Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abionyx Pharma (LTS:0RAG) has a Days Payable of 155.15 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abionyx Pharma and its competitors. This is near median its historical median of 162.90. Over the past decade, Abionyx Pharma's Days Payable has ranged from 149.38 to 2,244.40. According to the industry distribution chart, Abionyx Pharma ranks #299 out of 704 companies in the Biotechnology industry, placing it in the top 42.5%.
Is Abionyx Pharma's Days Payable too high?
Abionyx Pharma's current Days Payable of 155.15 is near median its 10-year median of 162.90. Over the past 10 years, this metric has ranged from a low of 149.38 to a high of 2,244.40. The Biotechnology industry median Days Payable is 113.56. Abionyx Pharma's value of 155.15 is 36.6% above this industry median. Based on the distribution chart, Abionyx Pharma ranks #299 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abionyx Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abionyx Pharma ranks #299 out of 704 companies for Days Payable. This puts Abionyx Pharma in the upper half of its industry. The industry median Days Payable is 113.56. Abionyx Pharma's value of 155.15 is 36.6% above this benchmark. Historically, Abionyx Pharma's own Days Payable has ranged from 149.38 to 2,244.40 over the past decade. While the company's 10-year median is 162.90 vs. the industry median of 113.56, Abionyx Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abionyx Pharma's current Days Payable of 155.15 is 36.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abionyx Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abionyx Pharma's current Days Payable is 155.15, which is near median its own 10-year median of 162.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (LTS:0RAG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.85, compared to a current price of €2.11 — trading 147.6% above its estimated fair value. The current Days Payable is 155.15, which is near median its 10-year median of 162.90 and 36.6% above the Biotechnology industry median of 113.56. Abionyx Pharma's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Abionyx Pharma (LTS:0RAG), the current Days Payable is 155.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abionyx Pharma (LTS:0RAG) Overvalued in 2026?
Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued.
The current stock price of €2.11 is trading 147.6% above its estimated GF Value™ of €0.85.
GuruFocus considers Abionyx Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0RAG:
Days Payable: 155.15 (near median its 10-year median of 162.90)
GF Value™: €0.85 vs. price of €2.11 (147.6% above fair value)
Industry Position: 36.6% above the Biotechnology median (#299 of 704)
No single metric tells the full story. See the LTS:0RAG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
29GF Score
Get the complete analysis for LTS:0RAG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAG has been successfully added to your 
